Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
106.15
+1.41 (1.35%)
Sep 2, 2026, 9:56 AM EDT - Market open
Rhythm Pharmaceuticals Revenue
Rhythm Pharmaceuticals had revenue of $71.26M in the quarter ending June 30, 2026, with 46.91% growth. This brings the company's revenue in the last twelve months to $239.92M, up 53.51% year-over-year. In the year 2025, Rhythm Pharmaceuticals had annual revenue of $189.76M with 45.83% growth.
Revenue (ttm)
$239.92M
Revenue Growth
+53.51%
P/S Ratio
30.06
Revenue / Employee
$579,512
Employees
414
Market Cap
7.31B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 189.76M | 59.63M | 45.83% |
| Dec 31, 2024 | 130.13M | 52.70M | 68.06% |
| Dec 31, 2023 | 77.43M | 53.79M | 227.56% |
| Dec 31, 2022 | 23.64M | 20.48M | 649.46% |
| Dec 31, 2021 | 3.15M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Caris Life Sciences | 989.61M |
| TG Therapeutics | 799.54M |
| Mirum Pharmaceuticals | 618.07M |
| Travere Therapeutics | 591.33M |
| ImmunityBio | 165.79M |
| CG Oncology | 6.23M |
RYTM News
- 5 days ago - Rhythm Pharmaceuticals initiated with a Hold at Deutsche Bank - TheFly
- 9 days ago - Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan - GlobeNewsWire
- 16 days ago - Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer - GlobeNewsWire
- 21 days ago - Rhythm Pharmaceuticals Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 27 days ago - Rhythm Pharmaceuticals price target raised to $155 from $141 at RBC Capital - TheFly
- 4 weeks ago - Rhythm Pharmaceuticals price target raised to $154 from $151 at Canaccord - TheFly
- 4 weeks ago - Rhythm Pharmaceuticals price target raised to $143 from $142 at Citi - TheFly
- 4 weeks ago - Rhythm Pharmaceuticals price target raised to $160 from $155 at Citizens - TheFly